VANCOUVER, British Columbia, May 02, 2018 (GLOBE NEWSWIRE) -- LeanLife Health Inc. (the “Company”, or “LeanLife”) (CSE:LLP) is pleased to announce that the processing and manufacturing equipment to make the Company’s Omega 3 products has been delivered to LeanLife’s production facility in Vancouver, British Columbia.

The equipment will be used to convert raw flaxseed oil into oils with qualities unavailable from standard flaxseed ingredients. Further processing by LeanLife will convert some of the oils into emulsions and powders. All products are designed for use in making and/or fortifying a wide variety of commercial foods, including bread, noodles, yogurt and cheese.

LeanLife leased a 4,000 sq. ft. facility in Vancouver earlier this year featuring excellent access to major road systems and other local infrastructure. The Company will continue to add services and leasehold improvements to enable the commissioning and startup of the equipment.

In addition to the production facility, a temporary laboratory has been established in the Vancouver area where testing is ongoing prior to initializing production.

“We are very pleased to have a full suite of equipment on-site and look forward to initial Omega 3 oil test production in the near future,” commented Stan Lis, Chief Executive Officer of LeanLife Health. “Preparation for operating the production facility is progressing smoothly and we are excited about our next steps, which include commercial permitting and obtaining food industry certifications for our product line.”

About LeanLife Health and the Omega 3 Market

LeanLife Health’s products are extracted from flax seeds, a plentiful and non-animal source of Omega 3. The products can be used as a food additive or as a nutraceutical and can be incorporated in foods such as bread, noodles, cheese, yogurt, juice and milk products. LeanLife Health’s industry leading Omega 3 product formulations are of the highest quality and contain no cholesterol. Products are available in oil, emulsion and powder forms.

The global omega 3 market is expected to reach USD 7.32 billion by 2020, according to a report by Grand View Research, Inc.

For more information, please contact:

Stan Lis, CEO 

Tel: 604 764-0518

E-mail: slis@leanlifehealth.com

Forward Looking Information

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control including, the Company's ability to compete with large food companies; sales of any potential products developed will be profitable; the ability to complete sales under the sales agreement. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.

THE CSE HAS NEITHER APPROVED NOR DISAPPROVED THE INFORMATION CONTAINED HEREIN AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE